Complete List of GLP-1 Receptor Agonists: Every Approved Drug in

GLP-1 receptor agonists have transformed treatment of both type 2 diabetes and obesity. But the class includes more medications than most people realise — from once-weekly injections to daily pills. Here is a complete guide to every GLP-1 medication currently available or in late-stage development.

How GLP-1 Receptor Agonists Work

GLP-1 is a naturally occurring incretin hormone secreted by the gut in response to eating. It stimulates insulin secretion, suppresses glucagon (which raises blood sugar), slows gastric emptying, and signals satiety to the brain. GLP-1 receptor agonists bind to and activate the same receptors, producing these effects at greater magnitude and for longer than the natural hormone.

Complete List of Approved GLP-1 Receptor Agonists (2026)

Next-Generation GLP-1 Agents in Development

Retatrutide (Eli Lilly): A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials showed up to 24% body weight loss — potentially the most effective agent in development. Not yet approved.

Orforglipron (Eli Lilly): An oral non-peptide GLP-1 agonist. Unlike Rybelsus, it does not require special administration conditions. Phase 3 results show comparable efficacy to injectable semaglutide. Could dramatically expand access if approved.

Cagrilintide/sema combo (CagriSema, Novo Nordisk): Combines semaglutide with cagrilintide (an amylin analogue). Phase 3 data showed up to 22% body weight loss. Could be approved 2026–2027.

Semaglutide: Why It Dominates

Semaglutide (Ozempic/Wegovy) has become the dominant GLP-1 agent due to its combination of high efficacy (~15% average weight loss), once-weekly dosing, robust long-term cardiovascular data, and — crucially — the availability of compounded versions that make it accessible at $149–$299/month versus $900–$1,400 for brand-name alternatives.

GLP-1 Supplements: Not the Same Thing

Some supplements are marketed as “GLP-1 boosters” or “natural GLP-1 support.” These are not GLP-1 receptor agonists — they cannot bind to GLP-1 receptors. They may support the body’s natural GLP-1 production via dietary fibre, probiotics, and botanical ingredients. Results are far more modest than prescription GLP-1 medications.

Affiliate disclosure: This article contains affiliate links. See our Affiliate Disclosure.

How GLP-1 Medications Compare: Key Differences

While all GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, they differ significantly in their potency, dosing frequency, delivery method, and clinical outcomes. Semaglutide and tirzepatide represent the newest generation and produce substantially greater weight loss than older agents like exenatide and liraglutide.

Dosing frequency ranges from twice daily (exenatide immediate release) to once weekly (semaglutide, dulaglutide, tirzepatide). The trend in GLP-1 development has been toward longer-acting formulations that improve patient adherence and maintain more stable blood levels of the medication.

Tirzepatide is unique among this class because it is a dual GIP/GLP-1 receptor agonist, meaning it targets two incretin pathways simultaneously. This dual mechanism contributes to its superior weight loss results in clinical trials, with patients achieving up to 22.5% body weight reduction in the SURMOUNT trials. Learn more in our which GLP-1 works better.

Choosing the Right GLP-1 Medication

Selecting the best GLP-1 medication depends on several factors including your primary treatment goal (diabetes management vs weight loss), insurance coverage, budget, tolerance for injections, and any existing health conditions.

For weight loss as the primary goal, semaglutide (Wegovy) and tirzepatide (Zepbound) have the strongest clinical evidence. For type 2 diabetes management with moderate weight loss, dulaglutide (Trulicity) and semaglutide (Ozempic) are both effective options with good insurance coverage.

If you prefer oral medication over injections, oral semaglutide (Rybelsus) is currently the only GLP-1 in pill form, though an oral version of Wegovy is in development. For patients who need a more affordable option, compounded semaglutide offers significant cost savings compared to brand-name medications.

Always discuss your options with a healthcare provider who can evaluate your complete medical profile. What works best for one patient may not be ideal for another, and factors like kidney function, thyroid history, and cardiovascular risk all influence the prescribing decision.